ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHEUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTR01

Tsepamo Next Generation: Optimizing HIV Treatment and Prevention Strategies for Pregnant Women in Botswana

Active
Institution
HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH, MA
Principal investigator
Roger L Shapiro
Funding
$497K
Duration
2025–2030
Open portfolio

Moonbase score

Still being scored

Abstract

Project Summary/Abstract This study will address two critical questions related to pregnant women living with HIV and their infants: 1) can two-drug antiretroviral treatment (ART) be used safely and effectively among pregnant women living with HIV? and 2) how can we most efficiently identify those at risk and prevent HIV infection among pregnant women? For Aim 1, there is a need to research two-drug ART with dolutegravir/lamivudine (DTG/3TC) in pregnancy, particularly in resource-limited settings. Botswana's imminent transition to DTG/3TC for all adults presents a unique opportunity to study its effects on maternal weight gain, viral suppression in pregnancy, adverse birth outcomes, and vertical transmission. This aim can be efficiently accomplished within the existing Tsepamo Study surveillance system by creating an emulated clinical trial and by utilizing over 2,400 mother–child pairs with targeted specimen collection. For Aim 2, the Tsepamo surveillance infrastructure also provides an ideal mechanism to identify recently infected pregnant women. We will determine the drivers of incident HIV infections in this population by 1) performing phylogenetic analyses linked to nationwide cluster surveillance performed at the Botswana Harvard Health Partnership (BHP), including evaluation of transmitted drug resistance, and 2) using in-depth interviews and questionnaires to understand current demographic and behavioral risk factors. Additionally, we will assess whether recent seroconverters would have been good candidates for / accepting of long-acting PrEP. Ultimately, the findings of this study will inform international guidelines, ensuring safer ART options for pregnant women that harmonize with adult treatment guidelines and inform upcoming strategies to roll out long-acting PrEP in high-risk women.

Research team

  • Roger L ShapiroPI
  • Rebecca Marie ZashPI

LOADING MOONBASE SCORE

R01HIV Comorbidities and Clinical Studies Study Section[HCCS]EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTpregnantwomenlong-actingdtgwomen livingbotswanapregnant womenhiv

Questions for HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH

Answered by the team behind this research.

No questions yet. Sign in to ask the first one

Related grants

Same researchers, same institution, same topic, scored first.